Anavex Life Ownership
| AVXL Stock | USD 9.74 0.19 1.91% |
Shares in Circulation | First Issued 2004-12-31 | Previous Quarter 84.8 M | Current Value 84.8 M | Avarage Shares Outstanding 31.8 M | Quarterly Volatility 29.4 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Anavex |
Anavex Stock Ownership Analysis
About 35.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 0.55. Anavex Life Sciences had not issued any dividends in recent years. The entity had 1:4 split on the 7th of October 2015. Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system diseases. The company was incorporated in 2004 and is headquartered in New York, New York. Anavex Lf operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 38 people. For more info on Anavex Life Sciences please contact the company at 844 689 3939 or go to https://www.anavex.com.Besides selling stocks to institutional investors, Anavex Life also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Anavex Life's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Anavex Life's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Anavex Life Quarterly Liabilities And Stockholders Equity |
|
Anavex Life Insider Trades History
Roughly 3.0% of Anavex Life Sciences are currently held by insiders. Unlike Anavex Life's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Anavex Life's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Anavex Life's insider trades
Anavex Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Anavex Life is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Anavex Life Sciences backward and forwards among themselves. Anavex Life's institutional investor refers to the entity that pools money to purchase Anavex Life's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Goldman Sachs Group Inc | 2024-12-31 | 538.5 K | Two Sigma Advisers, Llc | 2024-12-31 | 490.6 K | Pier Capital, Llc | 2024-12-31 | 441.9 K | Ubs Group Ag | 2024-12-31 | 418.8 K | Essential Planning, Llc. | 2024-12-31 | 413.1 K | Oz Management Llc | 2024-12-31 | 370.1 K | Citadel Advisors Llc | 2024-12-31 | 240.9 K | Bank Of New York Mellon Corp | 2024-12-31 | 220.2 K | Renaissance Technologies Corp | 2024-12-31 | 213.2 K | Blackrock Inc | 2024-12-31 | 6.6 M | Vanguard Group Inc | 2024-12-31 | 4.7 M |
Anavex Life Sciences Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Anavex Life insiders, such as employees or executives, is commonly permitted as long as it does not rely on Anavex Life's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Anavex Life insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Athanasios Skarpelos over a year ago Acquisition by Athanasios Skarpelos of 50000 shares of Anavex Life at 5.36 subject to Rule 16b-3 | ||
Christopher Missling over a year ago Exercise or conversion by Christopher Missling of 268000 shares of Anavex Life subject to Rule 16b-3 |
Anavex Life Outstanding Bonds
Anavex Life issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Anavex Life Sciences uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Anavex bonds can be classified according to their maturity, which is the date when Anavex Life Sciences has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View |
Anavex Life Corporate Filings
10Q | 12th of February 2025 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
F4 | 17th of January 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10K | 23rd of December 2024 Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance | ViewVerify |
8K | 30th of July 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Anavex Life Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Anavex Life. If investors know Anavex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Anavex Life listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Anavex Life Sciences is measured differently than its book value, which is the value of Anavex that is recorded on the company's balance sheet. Investors also form their own opinion of Anavex Life's value that differs from its market value or its book value, called intrinsic value, which is Anavex Life's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Anavex Life's market value can be influenced by many factors that don't directly affect Anavex Life's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Anavex Life's value and its price as these two are different measures arrived at by different means. Investors typically determine if Anavex Life is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Anavex Life's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.